Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line
therapy in patients with non-squamous advanced non-small cell lung cancer.